Agc1tm(IRES-CreERT2) mice express tamoxifen-inducible CreERT2 from the aggrecan promoter. These mice may be useful for studying cartilage degenerative diseases such as osteoarthritis and degenerative disk disease.
Benoit de Crombrugghe, UT MD Anderson Cancer Center
Genetic Background | Generation |
---|---|
N5+pN1F16
|
Allele Type | Gene Symbol | Gene Name |
---|---|---|
Targeted (Recombinase-expressing, Inducible) | Acan | aggrecan |
Starting at:
$278.00 Domestic price for female 4-week |
556.00 Domestic price for breeder pair |
The Agc1tm(IRES-CreERT2) allele has a CreERT2 sequence, and a frt-flanked neo cassette, inserted in the 3' untranslated region of the aggrecan (Acan) promoter/enhancer elements. Homozygous mice are viable and fertile. Aggrecan is an extracellular matrix protein expressed in the growth plate and articular cartilage, and fibrocartilage of the meniscus, trachea, and intervertebral disks. When Agc1creERT2 mice are bred with mice containing loxP-flanked sequence, tamoxifen-inducible, Cre-mediated recombination will result in deletion of the floxed sequences in the aggrecan-expressing cells of the offspring.
Recent studies have shown that the insertion of the CreERT2 cassette results in a deletion of 760 bp in the 3'UTR of the Acan gene. This results in a cre dosage-dependent reduction in body weight and body length by one month of age due to a reduction in the length of the growth plate and the thickness of articular cartilage. Due to this effect on skeletal growth, heterozygous Agc1+/cre should be used for conditional deletion of a target gene in the cartilage tissue.
The Cre-ERT2 fusion protein consists of Cre recombinase fused to a triple mutant form of the human estrogen receptor which does not bind its natural ligand (17β-estradiol) at physiological concentrations but will bind the synthetic estrogen receptor ligands 4-hydroxytamoxifen (OHT or tamoxifen) and, with lesser sensitivity, ICI 182780. Restricted to the cytoplasm, Cre-ERT2 can only gain access to the nuclear compartment after exposure to tamoxifen. To counteract the mixed estrogen agonist effects of tamoxifen injections, which can result in late fetal abortions in pregnant mice, progesterone may be co-administered.
A targeting vector was designed to insert an internal ribosome entry site (IRES)-CreERT2 fusion protein, a frt-flanked neomycin (neo) selection cassette, in reverse orientation, and an SV40 polyadenylation signal, into 3' untranslated region of the aggrecan (Acan) targeted gene. This construct was electroporated into (129S6/SvEvTac x C57BL/6NCr)F1-derived G4 embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6J blastocysts and chimeric males were bred with C57BL/6J females. The donating investigator reported that these Agc1tm(IRES-CreERT2) mutant mice were bred to C57BL/6J mice for at least 5 generations (see SNP note below). Upon arrival at The Jackson Laboratory, mice were bred with C57BL/6J inbred mice (Stock No. 000664) for at least one generation to establish the colony.
A 32 SNP (single nucleotide polymorphism) panel analysis, with 27 markers covering all 19 chromosomes and the X chromosome, as well as 5 markers that distinguish between the C57BL/6J and C57BL/6N substrains, was performed on the rederived living colony at The Jackson Laboratory Repository. While the 27 markers throughout the genome suggested a C57BL/6 genetic background, 4 of 5 markers that determine C57BL/6J from C57BL/6N were found to be segregating. These data suggest the mice sent to The Jackson Laboratory Repository were on a mixed C57BL/6J ; C57BL/6N genetic background.
Expressed Gene | cre/ERT2, Cre recombinase and estrogen receptor 1 (human) fusion gene, |
---|---|
Site of Expression | When these mice are bred with mice containing loxP-flanked sequence, tamoxifen-inducible, Cre-mediated recombination will result in deletion of the floxed sequences in aggrecan-expressing cells (the growth plate and articular cartilage, fibrocartilage of the meniscus, trachea, and intervertebral disks) of the offspring. |
Allele Name | targeted mutation 1, Benoit de Crombrugghe |
---|---|
Allele Type | Targeted (Recombinase-expressing, Inducible) |
Allele Synonym(s) | AgcCre; Agctm(IRES-CreERT-Neo-pgk; Agc1CreERT2); Agc1tm(IRES-creERT2) |
Gene Symbol and Name | Acan, aggrecan |
Gene Synonym(s) | |
Expressed Gene | cre/ERT2, Cre recombinase and estrogen receptor 1 (human) fusion gene, |
Site of Expression | When these mice are bred with mice containing loxP-flanked sequence, tamoxifen-inducible, Cre-mediated recombination will result in deletion of the floxed sequences in aggrecan-expressing cells (the growth plate and articular cartilage, fibrocartilage of the meniscus, trachea, and intervertebral disks) of the offspring. |
Strain of Origin | (129S6/SvEvTac x C57BL/6NCrl)F1 |
Chromosome | 7 |
Molecular Note | IRES-cre/ERT2 and an FRT-flanked PGK-neo selection cassette (in reverse orientation to the target gene) was inserted into the 3' UTR of the Aggrecan gene by homologous recombination in G4 ES cells.The line was established by breeding to C57BL/6 mice. The neo cassette was not removed. |
When maintaining a live colony, homozygous mice may be bred together. Due to cre dosage-dependent effects on skeletal growth, heterozygous Agc1+/cre should be used for conditional deletion of a target gene in the cartilage tissue.
When using the Agc1tm(IRES-CreERT2) mouse strain in a publication, please cite the originating article(s) and include JAX stock #019148 in your Materials and Methods section.
Service/Product | Description | Price |
---|---|---|
Heterozygous or wildtype for Acan<tm1(cre/ERT2)Crm> |
Frozen Mouse Embryo | B6.Cg-Acan<tm1(cre/ERT2)Crm>/J | $2595.00 |
Frozen Mouse Embryo | B6.Cg-Acan<tm1(cre/ERT2)Crm>/J | $2595.00 |
Frozen Mouse Embryo | B6.Cg-Acan<tm1(cre/ERT2)Crm>/J | $3373.50 |
Frozen Mouse Embryo | B6.Cg-Acan<tm1(cre/ERT2)Crm>/J | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.